Thermo Fisher Scientific Proceeds from disposition of marketable securities and other investments decreased by 80.9% to $250.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12400.0%, from $2.00M to $250.00M. This decline may warrant attention — for this metric, higher values are generally preferred.
Higher proceeds indicate the conversion of financial assets into cash, potentially to fund operations or debt repayment.
Represents cash inflows from the liquidation, maturity, or collection of financial investments. This provides a source o...
Standard investing activity; common across companies with active treasury management.
investing_proceeds_from_sale_maturity_and_collections_of_b77387| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q4 '24 | Q1 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $29.00M | $29.00M | $29.00M | $29.00M | $3.75M | $3.75M | $3.75M | $3.75M | $1.76B | $2.00M | $1.31B | $250.00M |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | -87.1% | +0.0% | +0.0% | +0.0% | >999% | -99.9% | >999% | -80.9% |
| YoY Change | — | — | — | — | -87.1% | -87.1% | -87.1% | -87.1% | >999% | — | -25.6% | >999% |